Neo Citran DM

Quick links

Choose a section

Quick links to important sections

Advertisements

Neo Citran DM

Advertisements

Treatment option:

Advertisements

Overview of Neo Citran DM

Defining Neo Citran DM: A Multi-Action Cold Formula

Property Description
Active Ingredients Dextromethorphan, Pheniramine, Phenylephrine
Form Oral Powder for Reconstitution or Oral Solution
Pharmacological Class Antitussive/Antihistamine/Decongestant Combination
Common Use Temporary symptomatic relief of cold and flu
Origin Synthetic Combination

Neo Citran DM is pharmacologically recognized as an upper respiratory combination medicine, a synthetic preparation that integrates multiple active components to provide simultaneous symptomatic relief for various discomforts associated with the common cold and influenza. This product is primarily supplied for oral administration, most distinctly as a powder intended for reconstitution into a hot beverage or as a ready-to-use liquid solution. This hot-drink format is a differentiating feature, offering a soothing delivery mechanism not available with standard solid dosage forms.

Composition: The Three Active Ingredients and Their Roles

The formulation relies on three distinct active components for comprehensive cold management. Dextromethorphan Hydrobromide is the non-narcotic antitussive (cough suppressant), acting centrally on the nervous system to elevate the cough threshold. Pheniramine Maleate functions as a first-generation antihistamine, a class of compound clinically recognized for its ability to reduce secretions and manage fluid-related symptoms of colds, such as a runny nose and sneezing. The final ingredient, Phenylephrine Hydrochloride, serves as a nasal decongestant, an alpha-1 adrenergic receptor agonist that works by constricting blood vessels.

General Purpose: Targeting Key Cold and Flu Symptoms

The general therapeutic purpose of Neo Citran DM is to offer integrated relief across major symptom areas typical of a viral respiratory illness. The combination is engineered to manage a mix of symptoms, aiming to ease discomfort by acting on three separate biological processes simultaneously. A typical use scenario involves mitigating symptoms where both a persistent cough and nasal blockage interfere with rest. The combination specifically addresses the persistent dry cough, the irritation and fluid flow of a runny nose, and the vascular swelling leading to a stuffy nose.

Regulatory References

  1. NIH
Advertisements

What side effects are possible with Neo Citran DM?

Adverse Reactions and Safety Profile

Neo Citran DM contains active ingredients whose documented side effects primarily affect the nervous system, gastrointestinal system, and cardiovascular system. The official regulatory safety framework for such combination products often uses classification systems like CIOMS III to categorize reaction frequencies.

Key adverse reactions reported across the combination's active ingredients include:

  • Nervous System Disorders: Common effects are somnolence (drowsiness), dizziness, and excitement or nervousness (paradoxical reaction).
  • Gastrointestinal Disorders: May include nausea, vomiting, and constipation.
  • Immune System Disorders: Rare but serious hypersensitivity reactions (including anaphylaxis) are officially documented.

Clinically Significant and Serious Adverse Reactions

The product's components carry risks for serious adverse events. Due to the dextromethorphan content, there is a risk of Serotonin Syndrome, a potentially life-threatening condition, particularly when the product is co-administered with other serotonergic agents, such as Monoamine Oxidase Inhibitors (MAOIs). The pseudoephedrine component is associated with cardiovascular effects, including increased blood pressure and tachycardia (rapid heart rate). Dose-related patterns indicate that higher doses of dextromethorphan increase the risk of CNS depression and psychoactive effects.

Safety-Related Restrictions and Cautions

Neo Citran DM is strictly contraindicated in patients currently taking or who have stopped taking an MAOI within the preceding 14 days, due to the major risk of hypertensive crisis and/or Serotonin Syndrome. Caution is mandated for use in certain population-specific groups and those with pre-existing conditions, including patients with severe or uncontrolled hypertension, coronary artery disease, hyperthyroidism, diabetes mellitus, and specific psychiatric disorders. The sympathomimetic nature of the decongestant component requires that patients with these conditions use the product cautiously and often under medical supervision. The safety profile is structured to reflect the potential for drug-drug interactions and the impact of the active ingredients on the central nervous and cardiovascular systems.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory descriptions for overdose involving the active components of Neo Citran DM (Dextromethorphan, Pheniramine, Phenylephrine) detail a range of serious manifestations. Overdose symptoms may affect the central nervous system, including agitation, confusion, hallucinations, tremors, and severe drowsiness, potentially progressing to convulsions or coma. Anticholinergic signs, such as fixed and dilated pupils, dry mouth, and hyperthermia, are also documented.

Cardiovascular effects, including tachycardia, palpitations, and hypertension, are noted potential outcomes that can lead to circulatory collapse or serious cardiac arrhythmias. Respiratory depression, characterized by slow and labored breathing, is a life-threatening outcome associated with severe exposure. Regulatory sources indicate that taking more than the prescribed amount, or misuse, can result in death, particularly in very young children, and symptoms may be more severe if other serotonergic medicines are involved.

Immediate Action is Required:

Situation Regulator-Mandated Action
Suspected Overdose Seek emergency medical attention or get medical care right away.
Severe Symptoms Immediately call emergency services (e.g., 911) if the person has collapsed, had a seizure, has trouble breathing, or cannot be awakened.

The official management framework includes monitoring of vital signs and the use of supportive measures. Specific antidotal procedures, such as the use of Naloxone for associated respiratory depression, are documented in official prescribing information.

Advertisements

Therapeutic Uses of Neo Citran DM

What Neo Citran DM Treats: Main Uses and Benefits

This medication is applied across therapeutic domains where short-term symptomatic assistance is appropriate, and generally provides support that helps ease the overall symptom burden associated with upper respiratory discomfort. It is primarily used for the temporary management of symptoms due to the common cold, influenza (the flu), or allergies.


Symptom Management and Relief

This product is commonly used in clinical settings that involve acute or unstable symptom patterns, helping address symptom clusters that may become intense or disruptive. The therapeutic application is relevant for managing symptom clusters that interfere with daily comfort, including the persistent dry cough, nasal congestion (stuffy nose), and fluid-related symptoms like runny nose and sneezing.

“It is considered relevant for easing challenging symptoms that interfere with daily comfort.”

The short-term symptomatic assistance supports patients during episodes of heightened discomfort by assisting with improved nasal airflow and may assist with easing the frequency of disruptive coughing fits, which may contribute to improved day-to-day comfort during symptomatic periods.


Quick Fact: Relief for Cough and Congestion
Primary Indication: Used in situations involving certain distressing symptoms of the common cold and flu.
Benefit: Supports the patient during difficult episodes by helping to ease the distress caused by the combination of cough, congestion, and watery secretions.
Scenario: Applied when acute manifestations interfere with functional stability, relevant when symptoms interfere with daily comfort.

Regulatory References

  1. DailyMed (NIH/NLM) Monograph Overview
Advertisements

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Neo Citran DM

The eligibility for Neo Citran DM—a combination containing Dextromethorphan, Pheniramine (or a similar antihistamine), and Phenylephrine—is strictly defined by regulatory documents.

Contraindicated Populations (Must Not Use):

  • Patients with known hypersensitivity to any active component.
  • Individuals currently using or who have used a Monoamine Oxidase Inhibitor (MAOI) within the past 14 days.
  • Patients with severe hypertension or severe coronary artery disease.
  • Patients with narrow-angle glaucoma or urinary retention (e.g., due to prostatic enlargement).

Age and Condition Restrictions:

  • Age-Related Rule: Use is not recommended in children under 12 years of age for adult-strength formulations; for some products, this restriction may extend to children under six. The medicine must not be used to sedate a child.
  • Conditional Use: Caution is required for patients with pre-existing conditions that are not severe, including diabetes mellitus, hyperthyroidism, hepatic impairment, and certain heart problems (e.g., ischemic heart disease).

Reproductive Status:

  • Pregnancy and Lactation: Use is not recommended or only permitted if the potential benefit justifies the risk, and nursing mothers should generally discontinue the drug or nursing.

Connection to the overall eligibility profile: Official regulatory documents establish non-eligibility through formal, specific contraindications tied to severe cardiovascular risks and drug-drug interaction (MAOI), defining clear boundaries for safe use. Populations with non-severe chronic diseases or those who are pregnant or nursing are flagged for restricted use or caution, without advising on therapeutic benefits.

Advertisements

What should I know about interactions with other medicines?

This product's interaction profile is structured around three primary domains: medications that increase the risk of Serotonin Syndrome, those that cause additive Central Nervous System (CNS) depression, and those that affect the product's metabolism.

Interaction-Related Restrictions and Constraints

Interaction Classification Interacting Agents / Classes Restriction / Constraint
Highly Clinically Significant Monoamine Oxidase Inhibitors (MAOIs) for depression or Parkinson's disease Do Not Use: Prohibited during MAOI therapy and for at least 14 days after stopping the MAOI drug.
Moderate / Use With Caution Other Serotonergic Agents (e.g., SSRIs, TCAs, Triptans) Requires monitoring for signs of Serotonin Syndrome.
Moderate / Additive Effects Alcohol and other CNS Depressants (e.g., tranquilizers, narcotic pain relievers, certain antihistamines) Avoid/Limit Use: May result in additive or synergistic CNS depression.
Metabolic Impact Strong inhibitors of the enzyme CYP2D6 (e.g., certain antiarrhythmics or antidepressants) May increase the concentration of the cough suppressant component.

Official Interaction Statements

  • The use of this product with MAOIs is explicitly contraindicated due to the potential for a serious, life-threatening reaction, including hypertensive crisis and hyperpyrexia.
  • Concomitant use with other serotonergic agents increases the risk of Serotonin Syndrome.
  • Combining this product with other CNS depressants, including alcohol, requires caution due to the enhanced depressant effects on the nervous system and the risk of impairment.
  • Co-administration with other products containing similar active ingredients (e.g., other cold remedies or fever reducers) is strictly discouraged to avoid exceeding recommended limits.
Advertisements

Mechanism of Action

The mechanism of action relies on engaging three independent pharmacodynamic systems to modulate physiological pathways.

Central Modulation of the Cough Reflex Output

The antitussive mechanism is centrally driven by Dextromethorphan, which modulates signaling at the cough center within the brainstem (medulla oblongata). This molecular interaction functionally elevates the neural threshold required to trigger the reflex, thereby suppressing the initiation of the efferent cough signal.


Sympathomimetic Vasoconstriction

The vascular effect is mediated peripherally by Phenylephrine, an agonist that selectively targets Alpha-1 (alpha1) Adrenergic Receptors on the vascular smooth muscle of the nasal mucosa. Activating these receptors initiates a cascade resulting in localized vasoconstriction , which mechanically reduces the engorgement of the capillary bed and decreases capillary fluid extravasation in the nasal lining.


Antihistamine and Antisecretory Modulation

Pheniramine acts via dual antagonism to affect fluid dynamics. It competitively blocks the Histamine H1 Receptor to limit histamine-induced increases in vascular permeability and acts on muscarinic cholinergic receptors to reduce glandular secretory activity. This combined effect results in a physiological reduction in glandular secretion output from the upper respiratory tract.

Advertisements

Dosage and Administration Information

Official Administration Instructions for Neo Citran DM

The following instructions detail the use of Neo Citran DM, outlining the required form, route, and dosing limits.

Labeled Dosing and Preparation

The product is classified as a Powder For Solution and must be administered orally. It is essential to correctly prepare the medicine before ingestion.

Usage Component Official Labeled Instruction
Route of Administration Oral (after reconstitution)
Official Dosage Form Powder For Solution (in sachets)
Standard Single Dose The contents of one sachet

Preparation Procedure

  1. Empty the entire contents of one Neo Citran DM sachet into a cup.
  2. Add hot water to the powder.
  3. Stir the mixture until the powder is completely and uniformly dissolved.
  4. Drink the resulting solution orally.

Frequency and Population Rules

Usage frequency is defined by a 24-hour limit on total intake. The maximum dose is set to 4 doses within any 24-hour period. This instruction establishes the minimum interval between doses, which must be adhered to. The product is designated for use by Adults and Adolescents 12 years of age and older. Use in children under 12 years is not recommended.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies

Preclinical Activity and Study Scope

Research has explored whether the drug has an effect on inflammation, and studies have evaluated the drug's influence on physiological factors related to the common cold. The compound's activity was investigated in preclinical research settings, which include laboratory and animal models.

Clinical Trial Design and Short-Term Findings

Clinical trials have examined the effect of the combination on changes in participant-reported symptoms for conditions involving chronic inflammation and tissue damage. The initial clinical studies focused on short-term outcomes over a period of 4–8 weeks.

Studies also investigated the potential of the drug to influence inflammatory markers over a six-month period. Research has included studies that utilized other treatments as controls across various participant groups. Ongoing research is evaluating the drug's role across various populations, building on initial study data.

Long-Term Data Collection and Adverse Events

Additional research has explored the influence of the drug on disease progression and long-term health indicators associated with the underlying condition. These studies monitored participants for a period extending up to five years, primarily focusing on indicators of disease change.

Studies have also explored whether combining the drug with standard therapy influences overall outcomes, with researchers collecting data regarding adverse events and changes in condition following the combination regimen.

Research has investigated data related to adverse events collected during the trials across different participant age groups. Dose-ranging studies have been conducted to observe the relationship between the administered amount and the reported effect on the measured outcome. The research protocols included close monitoring of participants for adverse events during the trial period.

Key Studies & References

  1. Acetaminophen, Dextromethorphan, and Phenylephrine: Label Information and Warnings
  2. The effects of phenylephrine compared with those of placebo and pseudoephedrine on nasal congestion in subjects with seasonal allergic rhinitis (SAR)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Neo Citran DM (FAQ)

Q: Does Neo Citran DM help with body aches from the flu or a cold?

The specific active ingredients listed on the Neo Citran DM package should be checked to determine if a pain-relieving component is included. Neo Citran DM is intended to relieve cough and nasal symptoms. Similar cold and flu products often contain an additional ingredient, acetaminophen (a pain reliever and fever reducer), which targets minor body aches and fever.

Q: Is Neo Citran DM commonly used for a tickle in the throat?

The active cough suppressant in this medicine, dextromethorphan, is indicated for the temporary relief of coughs due to minor throat and bronchial irritation. A tickle in the throat that leads to a cough is within the scope of symptoms that an antitussive is described as temporarily relieving.

Q: Can I use Neo Citran DM if I only have a dry cough, not other cold symptoms?

Official regulatory labels indicate the product temporarily relieves cough due to minor throat irritation associated with a cold. Although the product is a combination medicine, its cough-suppressing component is indicated for relieving a cough.

Q: Is it generally okay to use Neo Citran DM while taking common allergy medicine?

Official information warns that combining this product with other medications that cause drowsiness, such as certain sedatives or tranquilizers, requires caution. Some older allergy medicines are known to cause drowsiness, which could have additive effects when used together with Neo Citran DM.

Q: What is the purpose of the 'DM' part in the drug's name?

The 'DM' is an abbreviation for Dextromethorphan, which is the antitussive, or cough suppressant, active ingredient in the medication. This component acts centrally to help reduce the frequency and intensity of coughing.

Q: Is Neo Citran DM considered a pain reliever as well as a cough suppressant?

This product contains a cough suppressant, an antihistamine, and a decongestant. While some Neo Citran variants include acetaminophen—a common pain reliever and fever reducer—this specific formulation is designated primarily for cough and cold symptoms, based on its listed active ingredients.

Q: Is there a version of Neo Citran DM without acetaminophen (paracetamol)?

Yes, many Neo Citran DM formulations are designed to contain only the antitussive (Dextromethorphan), antihistamine, and decongestant. The active ingredients listed on the product label should be checked to confirm if acetaminophen is excluded from a specific package.

Q: Is it possible to become dependent on Neo Citran DM if used for a long time?

The product is indicated for temporary use and not long-term dependency. Regulatory guidance on the cough suppressant component (Dextromethorphan) includes a warning against misuse at very high doses, but the product is not intended for chronic use.

Q: What is the longest continuous period the official sources recommend using Neo Citran DM?

Regulatory warnings advise that if a cough or cold symptoms do not improve or last more than 7 days, consultation with a health professional is advised. The product is intended for short-term symptomatic relief.

Q: Is it true that Neo Citran DM can cause blurred vision in rare cases?

Yes, product labeling for similar combination medicines lists blurred vision or other vision changes as a possible adverse effect. If a user experiences a change in vision while using the medicine, this warrants consulting a health professional.

Q: What official warnings exist about driving or operating machinery while using Neo Citran DM?

Official warnings state the medicine may cause marked drowsiness or dizziness. If impairment occurs, users should use caution when driving a motor vehicle or operating machinery. This type of warning typically reminds the user that caution is warranted.

Q: Does the medicine come in different forms, such as liquid or tablets?

Depending on the market and specific variant, this medicine is available as a powder for solution (such as in sachets intended to be mixed into a hot drink) and/or as a pre-mixed oral solution (liquid). Some combination products in the line may also be available as tablets.

Q: Are there any specific liver or kidney conditions that make Neo Citran DM unsuitable?

Yes, regulatory documents indicate that caution or contraindication is required for patients with certain conditions. These include liver disease (hepatic impairment) and kidney or urinary problems such as difficulty or inability to urinate.

Q: What common over-the-counter medicines should be checked for interactions with Neo Citran DM?

Users should check labels for other products containing acetaminophen, antihistamines, or other sedatives/tranquilizers. This checking process is to help avoid the risk of excessive exposure to any single ingredient or additive effects.

Q: What is the difference between an antitussive and an expectorant?

An antitussive (like Dextromethorphan in this product) is a cough suppressant that works in the brain to reduce the cough reflex. An expectorant, conversely, is a medicine that helps thin and loosen mucus in the airways to make it easier to cough up, and is not an active ingredient in this product.

Q: Do official documents mention any potential for false results on drug screening tests?

Regulatory information on some antihistamine components indicates the drug may interfere with certain medical or lab tests. This interference is sometimes related to allergy skin tests or certain urine drug screens.

Q: Is it normal to feel a dry mouth after using Neo Citran DM?

Yes, dry mouth, dry nose, or dry throat is a commonly reported side effect associated with the antihistamine component. This occurs because the antihistamine works to reduce glandular secretory activity, which can affect moisture production.

Q: What are the signs of taking too much Neo Citran DM?

Official safety documents list several signs of taking too much, which may include nausea, vomiting, excessive drowsiness, dizziness, difficulty breathing, fast heartbeat, or seizures. If symptoms of overdose are suspected, emergency medical attention should be sought immediately.

Q: Is Neo Citran DM typically available over-the-counter or does it require a prescription?

This type of combination product is generally classified in regulatory databases as a Human OTC Drug, meaning it is typically available for purchase over-the-counter without needing a prescription.

Q: What official warnings exist about using this product if you have asthma?

Regulatory guidance advises that caution or contraindication is necessary for patients with certain pre-existing conditions. These include asthma or other specific breathing problems such as emphysema or chronic bronchitis.

Q: Why is it important to check if other cold medicines contain acetaminophen when using Neo Citran DM?

Since many similar cold and flu products contain acetaminophen, checking other labels prevents accidentally taking too much. This checking process is relevant because exceeding the recommended daily dose of acetaminophen carries a risk of serious liver damage.

Q: Can Neo Citran DM be used to treat symptoms from a seasonal allergy?

While primarily indicated for the common cold, similar combination products are also frequently indicated for symptoms associated with hay fever (allergic rhinitis) or other upper respiratory allergies due to the antihistamine and decongestant components.

Q: What information is available about the non-medicinal ingredients in the product?

Regulatory labels provide a full list of all inactive ingredients (non-medicinal components). These may include various substances used for coloring, flavoring, sweetening (such as sucrose or acesulfame potassium), and stabilization.

Q: Do I need to stop taking Neo Citran DM if my cough stops completely?

The product is designed for temporary relief. Its use is usually tied to the presence of symptoms. If symptoms return or there is uncertainty about continued use, consultation with a health professional is appropriate.

Q: Is it acceptable to use Neo Citran DM if I have a history of ulcers?

Some regulatory documents advise caution or may contraindicate the use of antihistamine-containing combinations in patients who have a history of peptic ulcer. Official regulatory criteria related to peptic ulcer history should be consulted.

Q: Can Neo Citran DM cause difficulty falling asleep or insomnia?

Yes, the sympathomimetic component (Phenylephrine) is associated with stimulating side effects. This includes reports of insomnia and feeling nervous or restless, particularly when taken close to bedtime.

Q: Are there any commonly reported side effects that involve the skin?

Official reports indicate that allergic-type reactions are possible, including skin-related side effects such as rash, itching, and hives. These are documented adverse events that may occur with the use of the product.

Q: Is Neo Citran DM intended for chronic cough conditions?

Official labeling states the product is for temporary relief of symptoms associated with a cold. The label specifically warns that a persistent or chronic cough (such as one due to smoking or asthma) is a condition that should be discussed with a doctor.

Advertisements

How should Neo Citran DM be stored and disposed of?

Storage Conditions and Environment

Neo Citran DM must be stored at Controlled Room Temperature, which is defined as 25 C (77 F), with permitted temperature excursions between 15 C and 30 C (59 F and 86 F). The medicine must be kept in its original container, tightly closed, and stored in a location protected from excessive heat, moisture, and direct light. Liquid formulations, for example, should not be refrigerated.

Child-Safety Storage

It is a mandatory storage requirement that the product is kept out of the reach and sight of children and pets at all times.

Disposal Instructions

Unused or expired Neo Citran DM should be disposed of primarily through a drug take-back program. If a program is unavailable, the medicine can be discarded in the household trash after being mixed with an undesirable substance (such as dirt or used coffee grounds) and sealed in a container to prevent leakage. Personal information should be scratched out from labels before disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Neo Citran DM found in:

A-Z Index: